Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2010 - 2026)
Madrigal Pharmaceuticals' (MDGL) quarterly Income from Continuing Operations came in at 92299000.0 in Q1 2026, down 26.03% year-on-year from 124772397.18 in Q1 2025, and up 46.33% on a QoQ basis from 171976000.0 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Income from Continuing Operations data on file, last reported at 92299000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 26.03% year-over-year to 92299000.0 in Q1 2026; TTM through Mar 2026 was 417632000.0, a 10.48% decrease from a year earlier, with the FY2025 full-year figure at 853782000.0, up 11.07% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 92299000.0, up from 171976000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MDGL reached as high as 42239000.0 in Q2 2025 and fell as low as 171976000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 94833588.24 across 5 years, with a median of 85905000.0 in 2022.
- On a YoY basis, Income from Continuing Operations climbed as much as 72.21% in 2025 and fell as far as 275.12% in 2025.
- Year by year, Income from Continuing Operations stood at 85905000.0 in 2022, then sank by 30.6% to 112194000.0 in 2023, then surged by 59.14% to 45845000.0 in 2024, then tumbled by 275.12% to 171976000.0 in 2025, then soared by 46.33% to 92299000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 92299000.0 in Q1 2026, 171976000.0 in Q4 2025, and 111118000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 15.54 Bn | - | -92.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.30 Mn |
| Dec 31, 2025 | -171.98 Mn |
| Sep 30, 2025 | -111.12 Mn |
| Jun 30, 2025 | -42.24 Mn |
| Mar 31, 2025 | -73.24 Mn |
| Dec 31, 2024 | -45.85 Mn |
| Sep 30, 2024 | -106.96 Mn |
| Jun 30, 2024 | -151.97 Mn |
| Mar 31, 2024 | -147.54 Mn |
| Dec 31, 2023 | -112.19 Mn |
| Sep 30, 2023 | -98.74 Mn |
| Jun 30, 2023 | -85.80 Mn |
| Mar 31, 2023 | -76.90 Mn |
| Dec 31, 2022 | -85.91 Mn |
| Sep 30, 2022 | -81.20 Mn |
| Jun 30, 2022 | -70.73 Mn |
| Mar 31, 2022 | -57.52 Mn |
| Dec 31, 2021 | -64.55 Mn |
| Sep 30, 2021 | -63.10 Mn |
| Jun 30, 2021 | -61.65 Mn |